News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR Annual Meeting 2007

Posted on: 04/18/2007

Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR Annual Meeting 2007 

Studies Show that TPI 287 Crosses the Blood-Brain Barrier and is Orally Active In Murine Models  BOULDER, Colo., April 15 /PRNewswire-FirstCall/ -- Tapestry
Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced the results of new
preclinical studies of TPI 287 at the 2007 Annual Meeting of the American
Association for Cancer Research (AACR). The data demonstrated that TPI 287,
an orally available next-generation taxane, crosses the blood-brain barrier
in rodents and demonstrates single agent activity and additive activity
with temozolomide in an orthotopic model of glioblastoma. In addition, the
drug demonstrated significant cytotoxic activity when administered either
orally or intravenously.
    "The treatment of glioblastoma with chemotherapeutic agents is hampered
by the inability of most drugs to penetrate the blood-brain barrier
sufficiently and deliver adequate drug exposure," commented Donald Picker,
Ph.D., president of Tapestry Pharmaceuticals. "We are very encouraged by
the preclinical data on rodent studies presented today as it demonstrates
the ability of this unique taxane to cross the blood-brain barrier and to
be orally bioavailable in murine models, which suggests the potential to
treat tumors not responsive to the currently marketed taxanes."
    The data were reported during a poster presentation entitled "TPI 287
crosses the blood brain barrier and contributes to antitumor activity in
the U251 glioblastoma intracranial tumor model in nude mice" and showed
that TPI 287:
    -- Crosses the blood-brain barrier
       Preclinical studies showed that TPI 287 accumulates in the brains of
       rats and mice. After a single intravenous dose of 20 mg/kg of TPI 287,
       the maximum drug concentration and area under the curve were several
       fold higher than the corresponding plasma values, and the clearance of
       the drug from the brain was slower than that found in plasma.

    -- Is orally active
       When TPI 287 was given orally in a flank model of glioblastoma, the
       percent tumor growth inhibition of 91% was similar to that of
       intravenous administration.

    -- Increases the efficacy of temozolomide in glioblastoma
       In an orthotopic brain xenograft study using the U251 glioblastoma cell
       line, a combination of low dose TPI 287 with temozolomide proved to be
       more efficacious than temozolomide alone, increasing the percent
       increased life span from 380% for temozolomide alone to 650% for a low
       dose of TPI 287 in combination with temozolomide (p = 0.046).  TPI 287
       alone showed activity that was statistically different from control but
       not as active as temozolomide alone.

    -- Demonstrates greater cytotoxic effect than other taxanes in
       In the SK-N-FI neuroblastoma xenograft model, which is inherently
       resistant to chemotherapy, TPI 287 was shown to be more active than
       other taxanes.  TPI 287 demonstrated 89% tumor growth inhibition,
       higher than the tumor growth inhibition rates observed for paclitaxel
       (13%), docetaxel (24%) and Abraxane(R) (38%).
    About TPI 287
    TPI 287 is a proprietary next-generation taxane being studied for the
treatment of various forms of cancer. In preclinical testing, TPI 287 has
demonstrated the ability to inhibit tumor cell growth in a number of in
vitro cell lines. In some cell lines resistant to taxanes, TPI 287 has
demonstrated greater inhibition of tumors in certain animal xenograft
models when tested against standard comparative agents. The in vitro
activity was seen across multiple cell lines, including cell lines known to
be sensitive to taxanes and cell lines known to be resistant to taxanes.
Taxane sensitive cell lines in which TPI 287 has shown activity include
cell lines derived from breast, uterine and non-small cell lung cancer.
Taxane resistant cell lines in which TPI 287 shows greater activity than
standard comparative agents include lines derived from breast and colon
    TPI 287 is currently in clinical studies in the United States. Tapestry
plans to initiate multiple Phase II trials for TPI 287 in 2007.
    About Tapestry Pharmaceuticals, Inc.
    Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused
on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry's
web site at
    Forward-Looking Statements
    Statements in this press release that are not historical facts are
"forward-looking statements" that involve risks and uncertainties. Forward-
looking statements can be identified by the use of words such as
"opportunities," "trends," "potential," "estimates," "may," "will,"
"should," "anticipates," "expects," "hopes" or comparable terminology or by
discussions of strategy. Such forward-looking statements include the
statements suggesting that TPI 287 may have utility in brain tumor
treatment and to treat tumors not responsive to currently marketed taxanes,
and that the Company plans to initiate multiple Phase II trials for TPI 287
in 2007. Such statements involve known and unknown risks, uncertainties and
other factors that may cause our actual results, performance or
achievements to be materially different from the results, performance or
achievements expressed or implied by such forward- looking statements. Such
risks, uncertainties and other factors include risks that clinical trials
for TPI 287 will be delayed due to institutional approvals, patient
recruitment, formulation and manufacturing difficulties, delays in
finalizing and receiving approval of Phase II protocols, negotiations with
regulatory agencies, or other factors; that human clinical trials may show
that TPI 287 is unsafe and/or ineffective in treating cancer in humans.
General implementation risks associated with development of TPI 287 include
those that we are blocked or limited in the development of TPI 287 because
of the intellectual property rights of third parties; that we are limited
in our ability to obtain, maintain and enforce our own intellectual
property; that development of TPI 287 is delayed or terminated because the
costs of further development exceed its value; and that the Company's
resources will be insufficient to continue development. Additional risks,
uncertainties and other factors are identified under the captions "Risk
Factors" and "Special Note Regarding Forward-Looking Statements" in the
Company's reports filed from time to time with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year ended
December 27, 2006. The Company disclaims any intention or obligation to
update publicly or revise any forward-looking statements, whether as a
result of new or additional information, future events or otherwise.
    Contact:                            Investor:
    Tapestry Pharmaceuticals, Inc.      Lilian Stern
    Gordon Link                         Stern Investor Relations, Inc.
    Senior Vice President,              212-362-1200
    Chief Financial Officer   
    Elma Hawkins, Ph.D.                 Lloyd Benson/Dana Conti
    Communications and                  Schwartz Communications
    Corporate Development               781-684-0770

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557